-
1.
公开(公告)号:US20090082330A1
公开(公告)日:2009-03-26
申请号:US12234281
申请日:2008-09-19
申请人: Peter A. BLOMGREN , Kevin S. Currie , Seung H. Lee , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt , Zhongdong Zhao , Pavel E. Zhichkin , Douglas G. Stafford , Jeffrey E. Kropf
发明人: Peter A. BLOMGREN , Kevin S. Currie , Seung H. Lee , Scott A. Mitchell , Jianjun Xu , Aaron C. Schmitt , Zhongdong Zhao , Pavel E. Zhichkin , Douglas G. Stafford , Jeffrey E. Kropf
IPC分类号: C07D403/14 , C07D403/02 , C07D409/02 , C07D407/14 , C07D401/14 , C07D413/14 , A61K31/497 , A61K31/496 , A61K31/5377 , A61P29/00 , A61P37/00 , C12N5/06 , C12Q1/48 , A61P35/00 , A61P19/00
CPC分类号: C07D409/12 , C07D241/08
摘要: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译: 本文描述了抑制Btk的式I化合物。 描述了包含至少一种式I化合物的药物组合物以及选自载体,佐剂和赋形剂的至少一种药学上可接受的载体。 描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。 描述了确定样品中Btk的存在的方法。
-
公开(公告)号:US20130023499A1
公开(公告)日:2013-01-24
申请号:US13343624
申请日:2012-01-04
IPC分类号: A61K31/4985 , A61K31/625 , A61K31/5377 , A61K31/551 , A61K31/501 , A61P37/06 , A61P29/00 , A61P37/08 , A61P35/00 , A61P35/02 , A61P11/06 , A61P11/00 , A61P25/00 , A61K31/538 , C12N5/071 , C12N5/0781 , G01N33/573 , C07D487/04
CPC分类号: C07D487/04
摘要: Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B-cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
-